CLASS I ONGOING Drug recall · Reported 11 Mar 2026 · FDA Enforcement Report
Mojo Max Fusion XXX, 500 mg, one capsule per blister card recalled
Mohamed Hagar is recalling Mojo Max Fusion XXX, 500 mg, one capsule per blister card, distributed nationwide in the US. The recall was initiated on 8 Oct 2025 and the FDA has classified it as Class I.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0396-2026
- FDA event ID
- 97796
- Recalling firm
- Mohamed Hagar, Brooklyn Ctr, MN
- Classification
- Class I
- Status
- Ongoing
- Recall initiated
- 8 Oct 2025
- FDA classified
- 17 Mar 2026
- Reported
- 11 Mar 2026
- Type
- Voluntary: Firm initiated
- Customers notified by
- Reason category
- Labeling Errors
Timeline
| 8 Oct 2025 | Recall initiated by company | |
| 11 Mar 2026 | Published in enforcement report | +154 days |
| 17 Mar 2026 | Classified by FDA | +6 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Marketed Without an Approved NDA/ANDA-FDA analysis revealed undeclared sildenafil (13.1 mg/capsule) and tadalafil (13.8 mg/capsule).
Product as listed by the FDA
Mojo Max Fusion XXX, 500 mg, one capsule per blister card, 20 count box, Distributed by: Max Nutrition Inc. UPC 6 78945 36675 0
Where it was distributed
U.S. Nationwide
Questions about this recall
Why was it recalled?
Marketed Without an Approved NDA/ANDA-FDA analysis revealed undeclared sildenafil (13.1 mg/capsule) and tadalafil (13.8 mg/capsule).
Which lots are affected?
ALL LOTS, exp 12/31/2027
Where was it sold?
U.S. Nationwide
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class I mean?
Class I is the most serious FDA recall category: there is a reasonable probability that using the product will cause serious health consequences or death.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.